CBER User Fee Standards May Need To Differ From CDER's, Director Zoon Says
Executive Summary
The Center for Biologics Evaluation & Research may need a different set of user fee review parameters than the drug center, CBER Director Kathryn Zoon, PhD, suggested during a Dec. 7 FDA public meeting on the Prescription Drug User Fee Act
You may also be interested in...
RxHealth Value Seeking New Exec Director; Member Base Splintering?
The RxHealth Value coalition is searching for a new executive director following the departure of John Golenski
RxHealth Value Seeking New Exec Director; Member Base Splintering?
The RxHealth Value coalition is searching for a new executive director following the departure of John Golenski
Biologics Approval Time Drops To 19 Months In 2001
The average approval time for a new therapeutic/ vaccine biologic application in 2001 was 19 months, a five-month improvement over 2000